Smith & Nephew Buys Nucryst Pharma Assets For Initial $21 Million
11 Novembre 2009 - 11:36AM
Dow Jones News
Smith & Nephew PLC (SN.LN) said Wednesday its advanced wound
management unit has signed a definitive agreement to buy most of
the assets of Nucryst Pharmaceuticals Corp. (NCS.T) for an initial
$21 million, to be adjusted at closing for working capital
changes.
MAIN FACTS:
-Smith & Nephew will acquire the manufacturing assets from
Nucryst's Fort Saskatchewan, Canada operations and the intellectual
property estate.
-Terms of acquisition are pending approval by Nucryst
shareholders and the transaction is anticipated to close before the
end of the year.
-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296; ian.walker@dowjones.com
Grafico Azioni Nucryst (NASDAQ:NCST)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Nucryst (NASDAQ:NCST)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Nucryst Pharmaceuticals - Common Shares (MM) (NASDAQ): 0 articoli recenti
Più Nucryst Pharmaceuticals Corp. Articoli Notizie